Roche partners with Ibex Medical Analytics for AI-assisted cancer detection
The Israeli AI-based cancer diagnostics startup will jointly develop an embedded image analysis workflow for pathologists to help diagnose early cancer detection
Ibex’s Galen platform was recently granted Breakthrough Device Designation by the U.S. Food and Drug Administration, and is CE marked in Europe for breast and prostate cancer detection. Through this alliance, customers using Roche Digital Pathology will gain access to Ibex’s innovative tools, such as algorithms that analyze prostate and breast biopsies. The AI algorithms and digital workflows will enable pathologists to provide accurate, efficient and timely diagnoses for their patients, and support them in the detection and grading of cancer, identification of important non-cancerous features, case reporting, and more.
Ibex Medical Analytics' platform allows pathologists the ease of AI tools to make early cancer diagnoses. Photo: Ibex Medical Analytics
Roche delivers an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be assessed using automated clinical image analysis algorithms. The Roche Group is based in Basel, Switzerland, and is active in over 100 countries.
“Digital pathology provides the capability to introduce new, innovative ways for laboratories to improve quality and efficiency of cancer diagnosis. Together with Roche, we look forward to transforming pathology by delivering powerful AI-based tools to the fingertips of pathologists,” said Joseph Mossel, who serves as co-founder and CEO of Ibex Medical Analytics.
